Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group.
Pepe S, Rossi E, Trawinska M, Tatarelli C, Di Veroli A, Maurillo L, Romano A, Crescenzi SL, di Toritto TC, Tafuri A, Latagliata R, Scalzulli E, Andriani A, De Stefano V, Breccia M. Pepe S, et al. Among authors: andriani a. Ann Hematol. 2022 Jun;101(6):1275-1282. doi: 10.1007/s00277-022-04815-w. Epub 2022 Mar 22. Ann Hematol. 2022. PMID: 35318505
Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.
Breccia M, Andriani A, Montanaro M, Abruzzese E, Buccisano F, Cedrone M, Centra A, Villivà N, Celesti F, Trawinska MM, Massaro F, Di Veroli A, Anaclerico B, Colafigli G, Molica M, Spadea A, Petriccione L, Cimino G, Latagliata R. Breccia M, et al. Among authors: andriani a. Ann Hematol. 2017 Mar;96(3):387-391. doi: 10.1007/s00277-016-2884-7. Epub 2016 Nov 26. Ann Hematol. 2017. PMID: 27889820
Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up.
Di Veroli A, Buccisano F, Andriani A, Montanaro M, Latagliata R, Santoro C, Breccia M, Spirito F, Cedrone M, Anaclerico B, Leonetti Crescenzi S, Porrini R, De Muro M, Avvisati G, Tafuri A, Cimino G, Spadea A. Di Veroli A, et al. Among authors: andriani a. Leuk Res. 2018 Jun;69:18-23. doi: 10.1016/j.leukres.2018.03.016. Epub 2018 Mar 31. Leuk Res. 2018. PMID: 29625320 No abstract available.
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
Andriani A, Elli E, Trapè G, Villivà N, Fianchi L, Di Veroli A, Niscola P, Centra A, Anaclerico B, Montanaro G, Martini V, Aroldi A, Carmosino I, Voso MT, Breccia M, Montanaro M, Foà R, Latagliata R. Andriani A, et al. Hematol Oncol. 2019 Aug;37(3):291-295. doi: 10.1002/hon.2635. Epub 2019 May 30. Hematol Oncol. 2019. PMID: 31050810
Sequential occurrence of chronic myeloproliferative and lymphoproliferative neoplasms: a collaborative retrospective study by pH-negative MPN latial group.
Breccia M, Petriccione L, Tatarelli C, De Muro M, Trawinska MM, Santopietro M, Spadea A, Di Veroli A, Scalzulli E, Paciaroni K, Tafuri A, Latagliata R, Andriani A, Di Napoli A. Breccia M, et al. Among authors: andriani a. Leuk Lymphoma. 2022 Nov;63(11):2751-2753. doi: 10.1080/10428194.2022.2092859. Epub 2022 Jun 25. Leuk Lymphoma. 2022. PMID: 35758305 No abstract available.
Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
Vozella F, Siniscalchi A, Rizzo M, Za T, Antolino G, Coppetelli U, Piciocchi A, Andriani A, Annibali O, De Rosa L, Cimino G, La Verde G, De Stefano V, Cantonetti M, di Toritto TC, Petrucci MT. Vozella F, et al. Among authors: andriani a. Ann Hematol. 2021 Apr;100(4):1059-1063. doi: 10.1007/s00277-020-04374-y. Epub 2021 Feb 2. Ann Hematol. 2021. PMID: 33528611
Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis.
Rago A, Latagliata R, Montanaro M, Montefusco E, Andriani A, Crescenzi SL, Mecarocci S, Spirito F, Spadea A, Recine U, Cicconi L, Avvisati G, Cedrone M, Breccia M, Porrini R, Villivà N, De Gregoris C, Alimena G, D'Arcangelo E, Guglielmelli P, Lo-Coco F, Vannucchi A, Cimino G. Rago A, et al. Among authors: andriani a. Leuk Res. 2015 Mar;39(3):314-7. doi: 10.1016/j.leukres.2015.01.001. Epub 2015 Jan 12. Leuk Res. 2015. PMID: 25636356
Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase.
Latagliata R, Montagna C, Porrini R, Di Veroli A, Leonetti SC, Niscola P, Ciccone F, Spadea A, Breccia M, Maurillo L, Rago A, Spirito F, Cedrone M, De Muro M, Montanaro M, Andriani A, Bagnato A, Montefusco E, Alimena G. Latagliata R, et al. Among authors: andriani a. Eur J Haematol. 2016 Jun;96(6):643-9. doi: 10.1111/ejh.12674. Epub 2015 Sep 18. Eur J Haematol. 2016. PMID: 26277477
Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients.
Andriani A, Latagliata R, Anaclerico B, Spadea A, Rago A, Di Veroli A, Spirito F, Porrini R, De Muro M, Crescenzi Leonetti S, Villivà N, De Gregoris C, Montefusco E, Polverelli N, Santoro C, Breccia M, Cimino G, Majolino I, Mazzucconi MG, Vianelli N, Alimena G, Montanaro M, Palandri F. Andriani A, et al. Am J Hematol. 2016 Mar;91(3):318-21. doi: 10.1002/ajh.24269. Am J Hematol. 2016. PMID: 26748894 Free article.
141 results